华熙生物
(688363)
| 流通市值：159.72亿 | | | 总市值：159.72亿 |
| 流通股本：4.82亿 | | | 总股本：4.82亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,596,018,408.81 | 1,756,179,663.09 | 829,407,051.84 | 4,199,089,274.55 |
| 营业收入 | 2,596,018,408.81 | 1,756,179,663.09 | 829,407,051.84 | 4,199,089,274.55 |
| 二、营业总成本 | 2,451,826,898.24 | 1,637,063,792.57 | 752,718,280.03 | 3,825,862,023.08 |
| 营业成本 | 869,628,585.76 | 562,891,118.66 | 266,762,450.43 | 1,245,918,494.01 |
| 税金及附加 | 31,736,980.74 | 19,804,619.76 | 5,434,023.14 | 56,248,611.91 |
| 销售费用 | 866,221,031.71 | 599,201,796.04 | 263,396,266.72 | 1,514,819,690.96 |
| 管理费用 | 337,583,568.86 | 226,860,666.38 | 117,873,077.5 | 541,749,778.09 |
| 研发费用 | 324,781,153.48 | 211,932,581.97 | 85,785,951.08 | 472,143,898.89 |
| 财务费用 | 21,875,577.69 | 16,373,009.76 | 13,466,511.16 | -5,018,450.78 |
| 其中:利息费用 | 5,517,122.5 | 3,289,876.78 | 2,414,166.05 | 4,146,493.55 |
| 其中:利息收入 | 8,554,260.7 | 4,522,560.76 | 2,185,750.61 | 7,632,886.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -2,014,422.79 | 1,884,667.39 | -1,229,372.32 | 19,623,286.8 |
| 加:投资收益 | 32,104,472.96 | 23,257,825.62 | -4,267,265.76 | -5,471,394.65 |
| 资产处置收益 | 947,852.48 | 594,407.25 | 20,874.41 | 217,334.91 |
| 资产减值损失(新) | -10,798,845.1 | -10,501,507.41 | -44,246.88 | -108,053,142.71 |
| 信用减值损失(新) | -6,009,947.63 | -7,187,293.09 | -11,033,691.28 | -37,453,575.87 |
| 其他收益 | 32,692,891.49 | 27,266,599.15 | 10,763,089.18 | 91,002,552.57 |
| 四、营业利润 | 191,113,511.98 | 154,430,569.43 | 70,898,159.16 | 333,092,312.52 |
| 加:营业外收入 | 2,323,525.6 | 1,046,439.51 | 113,650.84 | 3,853,958.2 |
| 减:营业外支出 | 3,895,594.84 | 3,394,656.79 | 2,992,137.55 | 3,144,265.9 |
| 五、利润总额 | 189,541,442.74 | 152,082,352.15 | 68,019,672.45 | 333,802,004.82 |
| 减:所得税费用 | 3,283,491.15 | -1,082,245.37 | 3,014,967.1 | 42,653,634.43 |
| 六、净利润 | 186,257,951.59 | 153,164,597.52 | 65,004,705.35 | 291,148,370.39 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 186,257,951.59 | 153,164,597.52 | 65,004,705.35 | 291,148,370.39 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 186,090,554.08 | 152,789,535.21 | 64,654,739.6 | 292,058,565.6 |
| 少数股东损益 | 167,397.51 | 375,062.31 | 349,965.75 | -910,195.21 |
| 扣除非经常损益后的净利润 | 160,456,488.13 | 129,463,488.75 | 57,528,695.51 | 186,400,439.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.39 | 0.32 | 0.14 | 0.61 |
| (二)稀释每股收益 | 0.39 | 0.32 | 0.14 | 0.61 |
| 八、其他综合收益 | -74,758,854.7 | -57,284,446 | -20,527,812.3 | 38,976,111.47 |
| 归属于母公司股东的其他综合收益 | -74,758,854.7 | -57,284,446 | -20,527,812.3 | 38,976,111.47 |
| 九、综合收益总额 | 111,499,096.89 | 95,880,151.52 | 44,476,893.05 | 330,124,481.86 |
| 归属于母公司股东的综合收益总额 | 111,331,699.38 | 95,505,089.21 | 44,126,927.3 | 331,034,677.07 |
| 归属于少数股东的综合收益总额 | 167,397.51 | 375,062.31 | 349,965.75 | -910,195.21 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-30 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |